Risk and protective factors of acute kidney injury in decompensated cirrhotic patients with ascites on tolvaptan.

Tomomi KogisoYuri OgasawaraTakaomi SagawaMakiko TaniaiKatsutoshi Tokushige

Published in: JGH open : an open access journal of gastroenterology and hepatology (2021)

AKI incidence was increased in patients with decreased liver function and was associated with poor survival. PPI/H2 blocker or kanamycin/rifaximin treatment may reduce the risk of AKI.

Keyphrases

acute kidney injury
heart failure
risk factors
cell free
combination therapy
ejection fraction
acute heart failure
angiotensin converting enzyme